Cargando…
Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients
OBJECTIVE: One focus in the medical care of HIV-infected patients today is cardiovascular risk reduction. Metabolic disturbances occur frequently in patients taking protease inhibitors (PI) and are a major risk factor for atherosclerosis. With few published head-to head studies substance-specific di...
Autores principales: | Gyalrong-Steur, M, Bogner, JR, Seybold, U |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353428/ https://www.ncbi.nlm.nih.gov/pubmed/21463988 http://dx.doi.org/10.1186/2047-783X-16-2-85 |
Ejemplares similares
-
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010) -
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
por: Ross, Lisa L, et al.
Publicado: (2015) -
Post-licensing safety of fosamprenavir in HIV-infected children in Europe†
por: Judd, Ali, et al.
Publicado: (2014) -
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012) -
Insulin translates unfavourable lifestyle into obesity
por: Kolb, Hubert, et al.
Publicado: (2018)